NuGen Technologies has appointed Elizabeth Hutt chief executive officer, effective Nov. 1. She replaces Elizabeth Davila, who will remain a member of the company's board of directors.
Hutt, previously NuGEN's vice president of commercial operations, will "lead the company in the development and commercialization of its ... nucleic acid amplification and detection technologies," the firm said this week.
As part of the changes, Anne Kopf-Sill, vice president of product development, has been promoted to senior vice president of product development and operations.
Prior to joining NuGen, Hutt was vice president of sales and service for North America and Pacific Rimat Tripos. She has held US and European sales management positions with Affymetrix. She holds a BA in chemistry from Michigan State University and an MS in business administration from Central Michigan University.
Charis Eu Li Eng has been named chair of the Genomic Medicine Institute at The Cleveland Clinic Lerner Research Institute effective Sept. 1. She will oversee genomic research for all of Lerner's programs, including those in neuroscience, cancer, cardiovascular medicine, musculoskeletal issues, and digestive disease.
Eng comes to the Clinic from Ohio State University, where she was director of the Clinical Cancer Genetics Program and the Division of Human Genetics. She has an MD and PhD from the Universityof Chicago.